MX2020004536A - Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka). - Google Patents

Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).

Info

Publication number
MX2020004536A
MX2020004536A MX2020004536A MX2020004536A MX2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A
Authority
MX
Mexico
Prior art keywords
trka
inhibitors
pyrimidine derivatives
receptor kinase
tropomyosin receptor
Prior art date
Application number
MX2020004536A
Other languages
English (en)
Inventor
Eid Sameh
Simone Fulle
Benjamin Merget
Samo Turk
Original Assignee
Biomed X Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed X Gmbh filed Critical Biomed X Gmbh
Publication of MX2020004536A publication Critical patent/MX2020004536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a nuevos inhibidores de TrkA de la formula (1) que son utiles en el tratamiento o prevencion del dolor agudo y cronico, pero tambien para otras actividades anormales de TrkA, mas alla de la terapia del dolor, tales como inflamacion y cancer.
MX2020004536A 2017-11-23 2018-11-22 Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka). MX2020004536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203290 2017-11-23
PCT/EP2018/082183 WO2019101843A1 (en) 2017-11-23 2018-11-22 Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors

Publications (1)

Publication Number Publication Date
MX2020004536A true MX2020004536A (es) 2020-08-03

Family

ID=60484137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004536A MX2020004536A (es) 2017-11-23 2018-11-22 Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).

Country Status (10)

Country Link
US (1) US20200399250A1 (es)
EP (1) EP3672957A1 (es)
JP (1) JP2021504462A (es)
KR (1) KR20200090198A (es)
CN (1) CN111247139A (es)
BR (1) BR112020010120A2 (es)
CA (1) CA3076444A1 (es)
MX (1) MX2020004536A (es)
RU (1) RU2020115534A (es)
WO (1) WO2019101843A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210016397A (ko) 2018-05-25 2021-02-15 에르덴 바놀루 신종 항암제 후보로서, 매우 강력한 tacc3 억제제
AU2022256380A1 (en) * 2021-04-12 2023-11-30 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
WO2023183520A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
HUP0400908A3 (en) * 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
CN101679386A (zh) * 2007-04-13 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
CA2688584A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP2674161A1 (en) * 2010-11-11 2013-12-18 Akron Molecules GmbH FMO3 inhibitors for treating pain
CN103622966A (zh) * 2012-08-24 2014-03-12 常辉 陶扎色替在制备治疗精神分裂症的药物中的用途

Also Published As

Publication number Publication date
CN111247139A (zh) 2020-06-05
WO2019101843A1 (en) 2019-05-31
EP3672957A1 (en) 2020-07-01
KR20200090198A (ko) 2020-07-28
CA3076444A1 (en) 2019-05-31
RU2020115534A (ru) 2021-11-08
US20200399250A1 (en) 2020-12-24
BR112020010120A2 (pt) 2020-11-10
JP2021504462A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
CO2020013599A2 (es) Piridazinonas como inhibidoras de parp7
CO2022010241A2 (es) Inhibidores de sos1
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CR20150633A (es) Derivados del bipirazol como inhibidores jak
PE20181303A1 (es) Compuestos que inhiben eif4a y metodos relacionados a los mismos
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
DOP2015000189A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
CO2019009722A2 (es) Dendrímeros terapéuticos
MX2020004536A (es) Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
ECSP23096498A (es) Restos de administración terapéutica novedosos y usos de estos
ECSP19066721A (es) Inhibidores duales de magl y faah
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.